A small Phase I study (NCT00471562, Table S1) of Ang-(1–7) as a first-in-class anti-angiogenic drug targeting Mas receptor, was undertaken in 18 patients with advanced solid tumors refractory to standard therapy with only one patient with lung cancer included [153]. This evidence concerns the gene ANG and lung cancer.